Journal
CANCER RESEARCH
Volume 72, Issue 23, Pages 6247-6256Publisher
AMER ASSOC CANCER RESEARCH
DOI: 10.1158/0008-5472.CAN-12-1444
Keywords
-
Categories
Funding
- NIH [R01CA69158, R01DK067333, R01DK065837]
- Mary Kay Ash Foundation
- V-Foundation
- Aurbach Endowment of the University of Virginia
- Jerry W. and Peggy S. Throgmartin Endowment of Indiana University
- Indiana Economic Development Fund
- Susan Komen Foundation
- Ligue Nationale Contre le Cancer (Equipe Labellisee LIGUE EL2011-AM)
- INCa [PLBIO08-126]
- Institut Curie
- INSERM
- CNRS
- Association pour la Recherche contre le Cancer
Ask authors/readers for more resources
TGF-beta derived from bone fuels melanoma bone metastases by inducing tumor secretion of prometastatic factors that act on bone cells to change the skeletal microenvironment. Halofuginone is a plant alkaloid derivative that blocks TGF-beta signaling with antiangiogenic and antiproliferative properties. Here, we show for the first time that halofuginone therapy decreases development and progression of bone metastasis caused by melanoma cells through the inhibition of TGF-beta signaling. Halofuginone treatment of human melanoma cells inhibited cell proliferation, phosphorylation of SMAD proteins in response to TGF-beta, and TGF-beta-induced SMAD-driven transcription. In addition, halofuginone reduced expression of TGF-beta target genes that enhance bone metastases, including PTHrP, CTGF, CXCR4, and IL11. Also, cell apoptosis was increased in response to halofuginone. In nude mice inoculated with 1205Lu melanoma cells, a preventive protocol with halofuginone inhibited bone metastasis. The beneficial effects of halofuginone treatment were comparable with those observed with other anti-TGF-beta strategies, including systemic administration of SD208, a small-molecule inhibitor of TGF-beta receptor I kinase, or forced overexpression of Smad7, a negative regulator of TGF-beta signaling. Furthermore, mice with established bone metastases treated with halofuginone had significantly less osteolysis than mice receiving placebo assessed by radiography. Thus, halofuginone is also effective in reducing the progression of melanoma bone metastases. Moreover, halofuginone treatment reduced melanoma metastasis to the brain, showing the potential of this novel treatment against cancer metastasis. Cancer Res; 72(23); 6247-56. (C) 2012 AACR.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available